Article ; Online: Cerebrospinal fluid CXCL13 concentration for diagnosis and monitoring of neurosyphilis in people with HIV.
2023 Volume 38, Issue 5, Page(s) 657–668
Abstract: Objectives: The study aimed to assess and compare cerebrospinal fluid (CSF)-CXCL13 levels in People with HIV (PWH) with suspected neurosyphilis (NS), those with syphilis but without NS, and patients without treponema infection. Additionally, it aimed to ...
| Abstract | Objectives: The study aimed to assess and compare cerebrospinal fluid (CSF)-CXCL13 levels in People with HIV (PWH) with suspected neurosyphilis (NS), those with syphilis but without NS, and patients without treponema infection. Additionally, it aimed to evaluate changes in CSF-CXCL13 concentrations before and after antibiotic treatment. Design: This was a prospective cohort study involving 93 PWH suspected of NS. All participants underwent lumbar puncture, with CSF-CXCL13 levels measured at baseline and during follow-up in patients diagnosed with NS. Methods: CSF-CXCL13 levels were quantified using ELISA. The Mann-Whitney U test was used to analyze differences between groups, while the Wilcoxon test assessed within subject changes. ROC curve analysis determined the diagnostic efficacy of CSF-CXCL13 for NS. Results: Significantly higher CSF-CXCL13 levels were observed in patients with NS compared to those with syphilis without NS and non-syphilis patients. Posttreatment, a decline in CSF-CXCL13 levels was noted in all NS cases. A CSF-CXCL13 threshold exceeding 60.0 pg/ml, in conjunction with reactive CSF-FTA-ABS, yielded a sensitivity of 88.9% and a specificity of 97.6% for NS diagnosis. Conclusions: CSF-CXCL13 emerges as a valuable adjunctive biomarker for detecting NS in PWH, especially in cases with nonreactive CSF-VDRL. Monitoring CSF-CXCL13 levels also appears effective in evaluating therapeutic response in PWH undergoing NS treatment. |
|||||
|---|---|---|---|---|---|---|
| MeSH term(s) | Humans ; Syphilis/complications ; Syphilis/diagnosis ; Syphilis/drug therapy ; Treponema pallidum ; Prospective Studies ; HIV Infections/complications ; Neurosyphilis/diagnosis ; Neurosyphilis/drug therapy ; Cerebrospinal Fluid ; Chemokine CXCL13/cerebrospinal fluid ; Chemokine CXCL13/therapeutic use | |||||
| Chemical Substances | CXCL13 protein, human ; Chemokine CXCL13 | |||||
| Language | English | |||||
| Publishing date | 2023-12-11 | |||||
| Publishing country | England | |||||
| Document type | Journal Article | |||||
| ZDB-ID | 639076-6 | |||||
| ISSN | 1473-5571 ; 0269-9370 ; 1350-2840 | |||||
| ISSN (online) | 1473-5571 | |||||
| ISSN | 0269-9370 ; 1350-2840 | |||||
| DOI | 10.1097/QAD.0000000000003813 | |||||
| Shelf mark |
|
|||||
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 2228: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.